Related Experiment Video

Updated: May 25, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer

Kevin D Courtney1, Mary-Ellen Taplin

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.

Current Opinion in Oncology
|February 14, 2012
PubMed
Abstract

Insights

Novel hormonal therapies targeting androgen signaling are improving outcomes for castrate-resistant prostate cancer (CRPC). New inhibitors of androgen synthesis and signaling show significant clinical benefits in patients with metastatic CRPC.

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Castrate-resistant prostate cancer (CRPC) remains a significant clinical challenge.
  • Androgen signaling pathways are crucial drivers of CRPC progression.
  • Effective second-line treatment options for CRPC are continuously being sought.

Purpose of the Study:

  • To review recent advancements in second-line hormonal therapies for CRPC.
  • To highlight the role of novel androgen signaling inhibitors and androgen synthesis inhibitors.
  • To summarize pivotal clinical trials and ongoing research in CRPC treatment.

Main Methods:

  • Literature review of recent studies on CRPC hormonal therapy.
  • Analysis of clinical trial data for novel agents.
  • Examination of the scientific rationale for targeting androgen signaling.

Main Results:

  • Novel inhibitors targeting androgen synthesis (e.g., abiraterone acetate) and signaling (e.g., MDV3100) demonstrate efficacy in CRPC.
  • Abiraterone acetate, a CYP17 inhibitor, is FDA-approved for metastatic CRPC post-docetaxel.
  • MDV3100 has shown a survival advantage in metastatic CRPC patients.

Conclusions:

  • Targeting extra-gonadal androgen synthesis and androgen receptor function is vital in CRPC.
  • New hormonal therapies have significantly improved clinical outcomes for metastatic CRPC patients.
  • Research continues to explore mechanisms of resistance and develop further therapeutic strategies.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...